Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

74cc6e5304819209377d83.VTMl7EH4Btqc6gOsGWCfwXk1C3FqeesBGv1vqG6bykE.AHJpohjKN-PMtVD6X1D9uC9NSgtaMpFSTqIH_Tzehwc-eHyCKJRsncmhaA~6b3bb2f7d3a78aaa7df9e84f8aeaf002
14/07 BofA Securities Adjusts Amgen Price Target to $312 From $307 MT
14/07 UBS Adjusts Price Target on Amgen to $420 From $400, Maintains Buy Rating MT
08/07 Morgan Stanley Adjusts Price Target Amgen to $333 From $340, Maintains Equalweight Rating MT
07/07 Truist Securities Adjusts Amgen Price Target to $340 From $327 MT
06/07 Rothschild & Co Redburn Adjusts Price Target on Amgen to $220 From $200 MT
19/06 Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says MT
16/06 Mizuho Securities Lifts Price Target on Amgen to $303 From $295, Keeps Outperform Rating MT
10/06 Morgan Stanley Adjusts Amgen Price Target to $340 From $332, Maintains Equal Weight Rating MT
20/05 Argus Adjusts Price Target on Amgen to $375 From $400, Maintains Buy Rating MT
14/05 Piper Sandler Adjusts Price Target on Amgen to $427 From $432, Maintains Overweight Rating MT
13/05 Daiwa Securities Adjusts Price Target on Amgen to $390 From $410, Maintains Outperform Rating MT
06/05 DZ Bank Lowers Its Price Target on Amgen Zonebourse
04/05 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
04/05 Guggenheim Adjusts Price Target on Amgen to $340 From $351, Maintains Neutral Rating MT
02/05 Amgen's Q1 EPS Beat Driven Lower Taxes, SG&A, Morgan Stanley Says MT
01/05 Morgan Stanley Lifts Price Target on Amgen to $332 From $326, Keeps Equalweight Rating MT
01/05 Goldman Sachs Adjusts Amgen Price Target to $425 From $415, Maintains Buy Rating MT
28/04 Morgan Stanley Adjusts Price Target on Amgen to $326 From $309, Maintains Equalweight Rating MT
21/04 Canaccord Genuity Initiates Amgen at Hold With $366 Price Target MT
14/04 UBS Adjusts Price Target on Amgen to $400 From $390, Maintains Buy Rating MT
09/04 Guggenheim Adjusts Amgen Price Target to $351 From $347, Maintains Neutral Rating MT
08/04 Viridian Therapeutics' Thyroid Eye Disease Franchise Maintains $1 Billion Opportunity, RBC Says MT
07/04 RBC Capital Adjusts Amgen Price Target to $370 From $360, Maintains Outperform Rating MT
03/04 Amgen's Diversification Continues To Pay Off, RBC Says MT
19/03 Wells Fargo Adjusts Price Target on Amgen to $390 From $375, Maintains Equalweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-1.06%
+5.85%
+1.75%
+7.06%
+8.62%
+0.2%
+26.2%
-2.31%
+20.47%
+17.59%
Average +8.44%
Weighted average by Cap. +6.80%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
360.45USD
Average target price
356.62USD
Spread / Average Target
-1.06%
High Price Target
427.00USD
Spread / Highest target
+18.46%
Low Price Target
215.00USD
Spread / Lowest Target
-40.35%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
UBS
Morgan Stanley
Truist Securities
Rothschild & Co Redburn
Mizuho Securities
Argus
Piper Sandler
Daiwa Securities
Guggenheim
Goldman Sachs
Canaccord Genuity
RBC Capital Markets
Wells Fargo Securities
Deutsche Bank Securities
TD Cowen
Leerink Partners
Citigroup
Cantor Fitzgerald
Oppenheimer
Bernstein
HSBC
BMO Capital
Scotiabank
DZ Bank
DBS Bank
Jefferies & Co.
Redburn Atlantic
JPMorgan Chase
Barclays
William Blair & Co.
Baird
Credit Suisse
DA Davidson
SVB Securities LLC
Cowen
Atlantic Equities
SVB Leerink
JPMORGAN Cory Kasimov
RBC Kennen Mackay
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
360.45USD
Average target price
356.62USD
Spread / Average Target
-1.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMGN Stock
  4. Consensus Amgen Inc.